Facts vs Fiction: the Role of Cannabinoids in the Treatment of Glaucoma

AbstractPurpose of ReviewMarijuana has been known to decrease intraocular pressure in humans since the early 1970s. However, its broad side effect profile, short half-life, and limited corneal penetration have prevented its development into a commercial ocular anti-hypertensive. Our paper aims to evaluate the latest research on the role of cannabinoids in the treatment of glaucoma and whether or not there is any progress in overcoming the above limitations.Recent FindingsSeveral techniques for retaining the therapeutic effect and minimizing or eliminating the side effects of Δ-9-tetrahydrocannabinol are being investigated, but these are still in the early stages.SummaryMuch work still needs to be done before a cannabinoid-based ocular antihypertensive is commercially available.

Source: Current Ophthalmology Reports - July 21, 2019 Category: Opthalmology Source Type: research